Skip to content

Epidaurus · Treatment Guide · Alternative & Complementary Medicine

Going abroad for —

Stem Cell Therapy Quality

Quality and legitimacy of stem cell programs

The country comparison

Which countries are best for stem cell therapy quality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 South Korea KR 4.5/5 Good South Korea combines world-class regulatory infrastructure, mandatory 5-year post-treatment surveillance, and substantial published clinical evidence from designated ARM institutions, supported by PIC/S-aligned GMP ma... Full report
    The evidence behind this score 7 cited points
    • MFDS established world's first real-time interactive adverse event reporting platform in 2021 for continuous safety tracking between manufacturers and practitioners
    • Mandatory 5-year post-treatment follow-up legislated for ARM institutions; cell therapies with animal cells require 30-year tracking
    • Three commercially approved stem cell products (Hearticellgram-AMI, Cartistem®, Queencell®) supported by Phase II/III clinical data
    • No FACT accreditation reported for non-hematopoietic regenerative stem cell therapies despite PIC/S GMP certification at leading manufacturers
    • South Korea ranks in global top five for stem cell research with extensive registered clinical trial participation; government investment ₩187.4 billion KRW annually
    • Informed consent framework does not mandate explicit disclosure that treatments are investigational or market-unapproved, as required by international standards
    • Wide pricing variation for approved products (₩5.7M–₩32M for Cartistem®) indicates inconsistent quality enforcement across expanding sector

    Read the full South Korea report →

  2. 2 United Arab Emirates AE 4.0/5 Good The UAE demonstrates good stem cell therapy quality anchored by ADSCC, a world-class facility with FACT, AABB, and JCI accreditation, GMP-certified laboratories, published peer-reviewed outcomes, and participation in ... Full report
    The evidence behind this score 5 cited points
    • ADSCC holds FACT, AABB, and JCI certifications achieved within 24 months (April 2024–March 2025), making it one of only two FACT-accredited centers in the entire Middle East
    • Published peer-reviewed research from ADSCC in Cell Stem Cell, Translational Medicine Communications, and Frontiers in Immunology demonstrates commitment to evidence-based practice
    • Four active registered clinical trials confirmed: OPERA (Type 1 Diabetes), PHOMS (MS), TIL observational study with Cleveland Clinic Abu Dhabi, and fertility exosome trial (NCT06841328)
    • GMP-certified laboratories with advanced equipment (CliniMACS Prodigy platforms, flow cytometry, mass cytometry) and structured post-treatment monitoring aligned with FACT/AABB accreditation requirements
    • Red flag: Quality is concentrated in Abu Dhabi; Dubai's broader cosmetic/wellness sector exhibits variable standards, imperfect enforcement of 2024 DHA advertising rules, and documented concerns about rogue clinics marketing unproven treatments

    Read the full United Arab Emirates report →

  3. 3 Germany DE 4.0/5 Good Germany demonstrates good quality standards with GMP-certified manufacturing facilities at major academic centers (Fraunhofer IZI, Charité BeCAT, DKFZ), strong practitioner qualifications including ISSCR participation... Full report
    The evidence behind this score 5 cited points
    • Fraunhofer IZI Leipzig operates GMP-certified facilities with 13 Grade B clean rooms, 4,500+ released cell products since 2006, and 14 completed regulatory inspections
    • Leading practitioners have ISSCR involvement: Andreas Kurtz serves as co-chair on ISSCR committees; Ludovic Vallier is Einstein Professor at Charité
    • Participation in multiple EU-registered clinical trials including VISICORT (MSC therapy, 700+ patients), geneTIGA (genome-edited T cells), and ReSHAPE (regulatory T-cell therapies)
    • Published outcomes data from 17 German CAR-T therapy centers with documented safety monitoring and complication protocols
    • Mandatory PEI regulatory oversight with ATMP authorization requirements, change notifications, donor screening database, and active enforcement demonstrated by March 2025 warning against unauthorized commercial ATMP treatment offers

    Read the full Germany report →

  4. 4 Spain ES 4.0/5 Good Spain's leading academic medical centers (Hospital Clínic Barcelona, ITRT Barcelona, Clínica Universidad de Navarra, Banc de Sang i Teixits) demonstrate world-class stem cell therapy standards with multiple GMP-certif... Full report
    The evidence behind this score 5 cited points
    • Banc de Sang i Teixits holds FACT-JACIE and FACT-NETCORD accreditations with ISO 9001 and AEMPS authorization; Clínica Universidad de Navarra holds AEMPS-accredited GMP laboratory and JCI accreditation
    • Hospital Clínic Barcelona reports 90% response rates for ARI-0001 in acute lymphoblastic leukemia with 500+ patients treated, published in high-impact journals; ITRT Barcelona has published 23 registered clinical trials cited 2,000+ times in peer-reviewed literature
    • Spain's TERAV network comprises 32 research groups across 14 GMP production facilities conducting trials in cardiovascular, neurodegenerative, and immune-inflammatory indications
    • AEMPS regulatory framework requires clinical efficacy evidence, GMP inspection, and pharmacovigilance plan approval before ATMP authorization, stricter than EU minimum standards
    • Report explicitly identifies dual-tier landscape with some private clinics offering less rigorously evidenced therapies and inconsistent transparency; Andalusian enforcement actions closed several unauthorized clinics

    Read the full Spain report →

  5. 5 United Kingdom GB 4.0/5 Good The UK has multiple JACIE-accredited facilities, GMP-certified laboratories, practitioners with specialist training, and extensive published outcomes from leading academic institutions, with participation in 193 activ... Full report
    The evidence behind this score 5 cited points
    • Multiple JACIE-accredited facilities including The London Clinic (first independent UK hospital with JACIE accreditation), King's College Hospital, Royal Marsden, Imperial College Healthcare, and HCA Healthcare UK
    • NHS Blood and Transplant operates four MHRA-licensed GMP laboratories with JACIE and HTA certifications; Great Ormond Street Hospital's Zayed Centre is one of the largest GMP-accredited manufacturing units globally
    • UK participates in 193 active ATMP clinical trials representing 57% of all European ATMP trials
    • Unregulated commercial sector: 80% of 24 examined clinics showed ethically problematic marketing; more than 2/3 disclosed no risks; none linked to completed clinical trials
    • Regulatory loophole: minimally-manipulated autologous same-session therapies exempt from ATMP classification, enabling ~38 commercial clinics to operate with minimal oversight

    Read the full United Kingdom report →

  6. 6 Israel IL 4.0/5 Good Israel demonstrates strong stem cell therapy quality at major academic medical centers, with GMP-certified laboratories, world-class practitioners publishing in top-tier journals, and structured clinical trial oversig... Full report
    The evidence behind this score 5 cited points
    • GMP-certified cell processing laboratories at Tel Aviv Sourasky's I-ACT (Ministry of Health certified July 2021) and Hadassah's hESC Research Center (FDA/European compliant QMS); JCI accreditation at major hospitals
    • Published peer-reviewed outcome data from Hadassah and Tel Aviv Sourasky in top-tier journals (JAMA Neurology for ALS, Brain for MS; NG-01 MS Phase 2 with 4-year follow-up showing 22/24 participants stabilized or improved)
    • 19 advanced therapy trials registered in MyTrial registry (2022) with multiple active Phase 3b, Phase 1/2a, and Phase 2 trials; structured Helsinki Committee and Ministry of Health oversight for all clinical trials
    • No FACT accreditation for non-hematopoietic stem cell programs identified; private sector regulation is 'less rigorous' with documented online advertising of unproven claims ('85% improvement in arthritis'); regulatory classification as 'lightly regulated' with enforcement gaps
    • Structured adverse event monitoring and follow-up protocols at academic centers (NurOwn and NG-01 trials documented as safe with no serious adverse events); however, no systematic, multi-year outcome tracking databases analogous to major transplant centers have been publicly documented outside of clinical trials

    Read the full Israel report →

  7. 7 Japan JP 4.0/5 Good Japan's academic sector ranks among the world's best in stem cell therapy quality, with Nobel laureate leadership at CiRA, first-in-world conditional approvals for iPSC therapies, 15 active national program clinical t... Full report
    The evidence behind this score 5 cited points
    • Keio University iPSC spinal cord injury trial demonstrated motor recovery in 2 of 4 completely paralyzed patients with clean 1-year safety monitoring
    • Japan granted world's first conditional marketing approvals for iPSC-derived therapies (AMCHEPRY, RiHEART) in 2026, evidence of clinical translation leadership
    • Private clinic adverse event reporting is approximately 1 per 100,000 administrations versus 1 per 3-4 for PMDA-approved regenerative medicine products—a ~30,000-fold gap indicating systemic under-reporting
    • 25% of examined Class II private clinic treatment plans cited predatory journals or lacked peer-reviewed evidence; 65% duplicated documentation across institutions
    • GMP-certified Cell Processing Center infrastructure exists and is expanding (REPROCELL, Fujifilm $200M investment), but widespread international accreditation (FACT/AABB) absent at private clinics

    Read the full Japan report →

  8. 8 Singapore SG 4.0/5 Good Singapore's institutional sector demonstrates excellent quality with FACT-accredited programs (NCIS, SGH), GMP-certified manufacturing facilities targeting international standards, practitioners with relevant credenti... Full report
    The evidence behind this score 5 cited points
    • NCIS holds FACT accreditation for IEC therapy (first in Asia); SGH holds FACT-JACIE for HSCT
    • ACTRIS operates 14 GMP-compliant clean suites targeting FDA, PIC/S, EMA, and ISCT standards; SCG Cell Therapy facility with 14 GMP clean suites and 80% reduction in manufacturing requirements
    • Published outcomes: NUS/SGH MSC orthopaedic trial (35 patients, 24.5-month follow-up) with significant functional improvement and no serious adverse events; CAR-T therapy achieved complete remission in 16 T-ALL patients
    • Participation in multiple registered clinical trials including SRD-001 (sole non-US Asian site), SCG101, and CytoMedTherapeutics trials
    • Private clinic quality gap: Artisan Regenerative Centre markets therapies for 40+ conditions including Parkinson's and Alzheimer's without verifiable practitioner credentials, published outcome data, or accreditation

    Read the full Singapore report →

  9. 9 United States US 4.0/5 Good The United States maintains exceptional stem cell therapy quality at FACT-accredited academic medical centers, with 319 accredited facilities, GMP-certified laboratories, specialized practitioner training, extensive p... Full report
    The evidence behind this score 5 cited points
    • 319 FACT-accredited organizations with over 90% of eligible US HPC facilities holding accreditation
    • Leading academic centers (Harvard, Stanford, UCLA, USC) with GMP-certified laboratories and active clinical trial participation publishing in peer-reviewed journals
    • Documented adverse events including at least 360 cases of injury or death from unproven stem cell treatments between 2004-2020, including 20 deaths and cases of blindness and contamination
    • Ninth Circuit 2024 ruling affirming FDA regulatory authority over stem cell products, with FDA green-lighting Omisirge, Lyfgenia, and Ryoncil for specific indications
    • Clear distinction in marketing between proven and experimental applications at accredited academic centers, but widespread unsubstantiated claims at unregulated clinics

    Read the full United States report →

  10. 10 Turkey TR 3.5/5 Moderate Turkey has world-class flagship facilities (Liv Hospital with GMP certification and JCI accreditation) and highly qualified practitioners (Prof. Karaöz with Harvard training and 190 publications), meeting some Score 4... Full report
    The evidence behind this score 5 cited points
    • Liv Hospital operates Turkey's first GMP-certified stem cell production center with JCI accreditation, meeting international standards
    • Prof. Erdal Karaöz: 190 published articles (133 international), H-index of 34, over 4,000 citations, trained at Harvard — world-class credentials
    • Ministry of Health approved clinical trials for multiple conditions; Turkish researchers published outcome data on 210 COVID-19 patients treated with UC-MSCs
    • Marketing transparency violation: clinics present experimental treatments as established treatments despite Ministry guidelines explicitly prohibiting this practice
    • Regulatory enforcement failure: described as 'wild west' with many clinics lacking oversight; facilities can make unsubstantiated claims without consequences

    Read the full Turkey report →

  11. 11 Jordan JO 3.5/5 Moderate Jordan's stem cell therapy quality is solidly moderate with significant institutional strengths offset by regulatory enforcement gaps. The Cell Therapy Center and KHCC operate with genuine international research stand... Full report
    The evidence behind this score 5 cited points
    • Cell Therapy Center has GMP-capable facilities with 143 iPSC cell lines registered in hPSCreg, demonstrating research-grade infrastructure; Professor Awidi holds 120+ publications with h-index of 25
    • Five ClinicalTrials.gov-registered trials demonstrate registered clinical research infrastructure: MS (NCT01895439, NCT03326505), Parkinson's (NCT03684122), and diabetes (NCT02940418), exceeding Score 3 requirements for 'few or no' trials
    • No facility holds confirmed FACT or equivalent international cellular therapy accreditation, a core Score 4 requirement; KHCC has JCI and CAP but aspires to cellular therapy-specific accreditation
    • Peer-reviewed literature explicitly documents private hospitals conducting stem cell trials 'without scientific merit, oversight, or participant protections' while misrepresenting them as licensed treatments
    • Final clinical outcome results from completed trials not yet published; academic protocols published but systematic outcome data from multiple facilities lacking

    Read the full Jordan report →

  12. 12 Poland PL 3.5/5 Moderate Poland has legitimate GMP-certified research institutions (PolTREG with CGMP certification, published EMA-approved trials showing 12-year safety data; PBKM with AABB accreditation and GMP authorization) and regulatory... Full report
    The evidence behind this score 5 cited points
    • PolTREG S.A. received CGMP certification from Polish Chief Pharmaceutical Inspectorate in March 2024; conducting EMA-approved Phase 2 trials (T1D, MS) with published long-term safety/efficacy data extending to 12 years
    • PBKM/FamiCord holds AABB accreditation (only laboratory of its class in Poland), GMP pharmaceutical manufacturing authorization, and ISO 9001:2008 certification
    • No FACT accreditation for commercial stem cell therapy identified at any Polish facility—explicitly noted as significant gap for international quality benchmark
    • Documented regulatory abuse 2011-2022: ~1,868 patients received unproven Wharton's jelly MSC injections for 95+ neurological diagnoses without immune compatibility testing or evidence-based protocols; vision loss cases reported to prosecutors
    • Recent reforms (2018-2023): biennial GIF inspections, 30-year batch record retention, mandatory adverse event reporting, 2023 ban on commercial charging of ATMP-HE participants

    Read the full Poland report →

  13. 13 Brazil BR 3.5/5 Moderate Brazil demonstrates world-class stem cell therapy infrastructure in its academic and hematopoietic cellular therapy sector—with FACT accreditation, GMP-certified manufacturing facilities, internationally recognized re... Full report
    The evidence behind this score 5 cited points
    • Five FACT-accredited institutions exist but all focus on hematopoietic cellular therapy; no FACT accreditation for the regenerative/MSC therapies medical tourists seek
    • Miheart study enrolled 1,200 cardiac patients in rigorous RCT showing no benefit over placebo; HUMAP published adipose-derived MSC case report for knee osteoarthritis—limited published outcomes compared to Score 4 expectation
    • Carthedrall CAR-T and MISSION! trials represent 2-3 active registered clinical trials, below Score 4 standard of 'at least 2-3' but below Score 5 standard of '5+ active trials'
    • ANVISA issued official public warning that only blood-forming stem cells are officially recognized as safe and effective outside clinical trials, yet commercial clinics market MSCs for ALS, Parkinson's, autism, and anti-aging applications
    • GMP-certified Nutera facilities and RDC 836/2023 regulatory framework demonstrate strong academic/regulated infrastructure, but enforcement of commercial sector compliance is documented as inconsistent at state level

    Read the full Brazil report →

  14. 14 Malaysia MY 3.0/5 Moderate Malaysia has genuine GMP-certified cell processing laboratories at multiple facilities (CTT, Beverly Wilshire, CryoCord, CELLAAX) meeting PIC/S standards, but lacks international cellular therapy accreditation. Practi... Full report
    The evidence behind this score 5 cited points
    • No FACT or equivalent international cellular therapy accreditation identified for non-HSCT regenerative stem cell therapy, despite GMP certification at multiple facilities
    • Most substantive published clinical evidence is a single 2024 nine-patient case series from ALPS Medical Centre; no controlled trials or multi-facility outcome studies from Malaysian non-HSCT providers
    • Governance rests entirely on MOH guidelines without enacted legislation; Malaysia has 'no specific enacted legislation for stem cell therapy,' limiting enforcement against the documented 'proliferation of private wellness clinics' offering unapproved treatments
    • GMP-certified laboratories at leading institutions (Cell Tissue Technology, Beverly Wilshire Medical) meet PIC/S/ISO 14644 Class 5 standards, establishing a competent manufacturing baseline
    • NPRA's updated 2025 CGTP framework classifies stem cell products as biological pharmaceuticals subject to full regulatory approval, but as of mid-2025 only one product had received full marketing approval

    Read the full Malaysia report →

  15. 15 Thailand TH 3.0/5 Moderate Thailand presents a moderate-quality stem cell therapy market with significant variation between providers. Leading academic medical centers (Chulalongkorn, Siriraj, Bumrungrad) maintain GMP-certified laboratories, JC... Full report
    The evidence behind this score 5 cited points
    • Thailand has 60+ JCI-accredited hospitals with regenerative medicine departments but zero FACT-accredited cellular therapy facilities, representing an international quality standard gap
    • Thai Medical Council stated 'Thailand ranks among countries deceiving patients with illegal stem cell treatments' with 400+ prosecutions annually for exaggerated claims and 2025 criminal convictions of a physician, clinic owner, and advertising agency
    • Regulatory enforcement gap: Ministry of Public Health permits stem cell treatments only for hematopoietic transplants for blood disorders, yet hundreds of clinics offer orthopedic, neurological, and anti-aging treatments outside this legal framework
    • Documented patient safety incident: 2006 kidney patient who developed tumor masses in kidney, liver, and adrenal glands after stem cell treatment and subsequently died
    • Academic centers at Chulalongkorn University and Siriraj Hospital demonstrate legitimate research and published outcomes for specific applications, but limited peer-reviewed outcome data from commercial facilities overall

    Read the full Thailand report →

  16. 16 Colombia CO 3.0/5 Moderate Colombia demonstrates moderate stem cell therapy quality with developing infrastructure including GMP-certified laboratories and practitioners with specialist training, but lacks the international cellular therapy acc... Full report
    The evidence behind this score 6 cited points
    • No FACT accreditation for any Colombian stem cell clinic; only ICONTEC certification and claims of cGMP compliance at leading facility (BioXcellerator)
    • GMP-certified laboratories at major treatment centers (BioXcellerator, LivCells, Stem Cells Colombia) but lacking international certification such as ISO 14644 Class 5
    • Limited published outcome data: one 2024 systematic review co-authored by BioXscience/BioXcellerator researchers, but no peer-reviewed clinic-specific outcome studies identified
    • Only one registered clinical trial on ClinicalTrials.gov (NCT05631444); overall clinical trial participation described as limited
    • FTC warning letter issued to BioXcellerator for unsubstantiated COVID-19 treatment claims; marketing for unproven neurological indications without clear distinction between investigational and proven applications
    • Expanded MSC therapies operate in regulatory grey area with INVIMA's oversight limited to tissue banking rather than therapeutic applications; enforcement described as inconsistent

    Read the full Colombia report →

  17. 17 Hungary HU 3.0/5 Moderate Hungary maintains a robust EU-aligned regulatory framework with ATMP oversight and three-tier ethics committees, but lacks FACT accreditation or equivalent cellular therapy certification at commercial facilities. Whil... Full report
    The evidence behind this score 5 cited points
    • No FACT accreditation identified for any therapeutic stem cell delivery program; KRIO Institute holds AABB accreditation only for cord blood banking (not therapeutic delivery)
    • No published peer-reviewed outcome data from commercial regenerative stem cell clinics; commercial clinics do not publicly display GMP certification numbers, ISO clean-room classification, or published outcomes
    • Clinical trial identifiers cited as ongoing by industry sources but not independently confirmed from open search results; systematic adverse event reporting documented only for registered trials, not off-trial commercial treatments
    • EU ATMP Regulation EC 1394/2007 provides regulatory floor with mandatory ethics review, but practitioners' regenerative medicine fellowship training is not institutionalized; report describes Hungary as 'lower-tier stem cell therapy medical tourism destination, well below Germany or South Korea'
    • 2009 criminal case involving unauthorized fetal stem cell treatments highlighted enforcement capacity but also indicated underlying vulnerabilities; no equivalent scandal reported 2015–2025

    Read the full Hungary report →

  18. 18 India IN 2.5/5 Moderate India exhibits poor overall stem cell therapy quality with significant regulatory enforcement gaps and hundreds of unregulated clinics offering unproven treatments, despite having comprehensive national guidelines on ... Full report
    The evidence behind this score 5 cited points
    • Only one facility in Gujarat has FACT-JACIE accreditation for cellular therapy (hematopoietic, not stem cell therapy specifically); no facilities have FACT accreditation for stem cell therapy programs
    • Hundreds of clinics offer unproven stem cell therapies despite stringent national guidelines, with only 5 out of 82 organizations achieving IC-SCR registration by 2013, indicating widespread lack of institutional oversight
    • Most private companies offering stem cell therapies publish no outcome data or peer-reviewed clinical results, with Advancells, Reelabs, and Regenexx providing no transparency on clinical outcomes or treatment parameters
    • Regulatory enforcement suffers from jurisdictional ambiguity: neither ICMR nor DBT has legislative authority over medical research, and DCGI faces challenges bringing unproven therapy activity outside recognized clinical trials under its remit
    • Substantial lack of adverse event reporting in India compared to US, EU, and Japan where deaths and serious complications have been documented, suggesting either inadequate monitoring systems or failure to report complications

    Read the full India report →

  19. 19 Mexico MX 2.0/5 Poor Mexico's stem cell therapy sector is characterized by a profound gap between regulatory requirements and enforcement. While COFEPRIS maintains a licensing framework and a small number of credentialed practitioners and... Full report
    The evidence behind this score 5 cited points
    • CDC documented clonal Mycobacterium abscessus infections in 3 U.S. patients treated at Mexican clinics in 2022, with treatment ongoing as of March 2024, indicating contaminated cell products and supply chain failures
    • Web surveillance study identified 76 confirmed stem cell clinics in Tijuana; only 1 clinic's COFEPRIS licensing claims could be verified, indicating 98.7% regulatory non-compliance
    • 99.1% of Tijuana stem cell clinic websites lacked academic institutional affiliation, indicating widespread lack of scientific legitimacy or transparency
    • Giostar, one of Mexico's largest clinic chains, has only 5 PubMed publications and no registered clinical trials despite years of operation, demonstrating absence of published evidence from commercial providers
    • COFEPRIS explicitly acknowledged lacking financial resources and trained personnel to effectively monitor the rapidly growing number of clinics, creating a regulatory enforcement gap

    Read the full Mexico report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for stem cell therapy quality, top to bottom. How we score →

  1. 5/5 Excellent

    - Multiple facilities with FACT accreditation or equivalent international certification for cellular therapy - GMP-certified laboratories with documented ISO 14644 Class 5 or better clean room standards - Practitioners with formal regenerative medicine fellowships from recognized programs - Published peer-reviewed outcome data from at least 3 leading facilities - Active participation in multiple registered clinical trials (5+ active trials on ClinicalTrials.gov) - Clear distinction in marketing between proven and experimental applications - Documented adverse event reporting system with publicly available safety data - Comprehensive patient screening protocols with documented contraindication criteria - Structured long-term follow-up programs with outcome tracking - Examples: Select facilities in USA, Germany, South Korea, Japan that meet all criteria

  2. 4/5 Good

    - At least one facility with international cellular therapy accreditation - GMP-certified laboratories at major treatment centers - Practitioners with relevant specialist training (orthopedics, hematology, neurology with stem cell focus) - Some published outcome data from leading facilities - Participation in at least 2-3 registered clinical trials - Generally transparent marketing with some evidence of quality distinctions - Adverse event monitoring systems in place at leading facilities - Structured patient screening at accredited centers - Follow-up protocols at major facilities

  3. 3/5 Moderate

    - No international cellular therapy accreditation but facilities meet basic national standards - Laboratory facilities meet domestic GMP requirements but not international certification - Practitioners have general medical qualifications with some regenerative medicine training - Limited published outcome data, mostly case reports rather than systematic studies - Few or no registered clinical trials, primarily clinical practice - Marketing may overstate evidence for some treatments - Informal adverse event tracking, no systematic reporting - Basic patient screening without standardized protocols - Variable follow-up practices

  4. 2/5 Poor

    - No accredited facilities; minimal quality oversight - Laboratory standards uncertain or below international norms - Practitioners lack specific regenerative medicine training - No published outcome data from domestic facilities - No participation in clinical trials - Marketing makes unsubstantiated claims about treatment efficacy - No systematic adverse event monitoring - Inadequate patient screening; treatments offered without proper evaluation - Little to no follow-up care - Reports of patient harm from treatments

  5. 1/5 Very Poor / Unavailable

    - No quality-controlled stem cell therapy facilities exist - Known problems with contaminated or misidentified cell products - Practitioners without appropriate medical credentials offering treatments - Active promotion of fraudulent or dangerous treatments - Documented significant patient harm from stem cell treatments - Government warnings against stem cell tourism to this country - No distinction between legitimate and illegitimate providers - OR: Stem cell therapies are completely prohibited and thus quality is not assessable

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source adscc.ae/who-we-are Cited in Stem Cell Therapy Quality in United Arab Emirates
  2. Untitled source alttreatment.io/2025/08/19/does-turkey-have-stem-cell-therapy-in-2025 Cited in Stem Cell Therapy Quality in Turkey
  3. Untitled source amedical.az/en/blogs/treatments-turkey/stem-cell Cited in Stem Cell Therapy Quality in Turkey
  4. Untitled source bi-maristan.com/en/articles/stem-cell-therapy-for-diabetes Cited in Stem Cell Therapy Quality in Turkey
  5. Untitled source bioinformant.com/stem-cell-clinics Cited in Stem Cell Therapy Quality in United States
  6. Untitled source calmatters.org/health/2024/10/stem-cell-therapy-fda Cited in Stem Cell Therapy Quality in United States
  7. Untitled source cayraclinic.com/treatment/stem-cell-treatment Cited in Stem Cell Therapy Quality in Turkey
  8. Untitled source clinicaltrials.gov/study/NCT03684122 Cited in Stem Cell Therapy Quality in Jordan
  9. Untitled source clinicsoncall.com/en/blog/everything-you-need-to-know-about-liv-hospitals-stem-cell-treatment Cited in Stem Cell Therapy Quality in Turkey
  10. Untitled source clinregs.niaid.nih.gov/country/india Cited in Stem Cell Therapy Quality in India
  11. Untitled source cromospharma.com/turkiye-a-hidden-gem-in-clinical-research Cited in Stem Cell Therapy Quality in Turkey
  12. Untitled source embryo.asu.edu/pages/singapore-bioethics-advisory-committee Cited in Stem Cell Therapy Quality in Singapore
  13. Untitled source expertchikitsa.com/listing/hospitals/turkey/top-10-stem-cell-therapy-hospitals-in-turkey-find-best-surgeon-cost-and-reviews Cited in Stem Cell Therapy Quality in Turkey
  14. Untitled source experts-medical.com/en/blog-en/stem-cell-therapy-turkey Cited in Stem Cell Therapy Quality in Turkey
  15. Untitled source globalstemcelltherapy.com/stem-cell-therapy-in-turkey Cited in Stem Cell Therapy Quality in Turkey
  16. Untitled source healthyturkiye.com/stem-cell-therapy-for-stroke-turkey Cited in Stem Cell Therapy Quality in Turkey
  17. Untitled source ibiotherapy.com/our-team/professor-erdal-karaoz Cited in Stem Cell Therapy Quality in Turkey
  18. Untitled source icloudhospital.com/articles/top-10-stem-cell-therapy-in-korea-what-you-need-to-know Cited in Stem Cell Therapy Quality in South Korea
  19. Untitled source immunotherapymx.com Cited in Stem Cell Therapy Quality in Mexico
  20. Untitled source int.livhospital.com/best-stem-cell-therapy-clinics-in-the-world Cited in Stem Cell Therapy Quality in Turkey
  21. Untitled source int.livhospital.com/stem-cell-care Cited in Stem Cell Therapy Quality in Turkey
  22. Untitled source int.livhospital.com/stem-cell-therapy Cited in Stem Cell Therapy Quality in Turkey
  23. Untitled source int.livhospital.com/stem-cell-treatment Cited in Stem Cell Therapy Quality in Turkey
  24. Untitled source internationalclinics.com/en/blog/Stem-Cell-Therapy-in-Turkey Cited in Stem Cell Therapy Quality in Turkey

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Alternative & Complementary Medicine

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Stem Cell Therapy Quality

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison